BR112012024232A8 - "aptâmero de 73 nucleotídeos ou menos, complexo, composição farmacêutica e medicamento anti-dor" - Google Patents

"aptâmero de 73 nucleotídeos ou menos, complexo, composição farmacêutica e medicamento anti-dor"

Info

Publication number
BR112012024232A8
BR112012024232A8 BR112012024232A BR112012024232A BR112012024232A8 BR 112012024232 A8 BR112012024232 A8 BR 112012024232A8 BR 112012024232 A BR112012024232 A BR 112012024232A BR 112012024232 A BR112012024232 A BR 112012024232A BR 112012024232 A8 BR112012024232 A8 BR 112012024232A8
Authority
BR
Brazil
Prior art keywords
aptamer
nucleotides
complex
less
pharmaceutical composition
Prior art date
Application number
BR112012024232A
Other languages
English (en)
Other versions
BR112012024232A2 (pt
Inventor
Nakamura Yoshikazu
Jin Ling
Hiramatsu Hisanao
Original Assignee
Fujimoto Seiyaku Kk
Ribomic Inc
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujimoto Seiyaku Kk, Ribomic Inc, Shionogi & Co filed Critical Fujimoto Seiyaku Kk
Publication of BR112012024232A2 publication Critical patent/BR112012024232A2/pt
Publication of BR112012024232A8 publication Critical patent/BR112012024232A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

APTÂMERO PARA NGF E USO DO MESMO. A presente invenção refere-se a um aptâmero de maior qualidade tendo uma atividade de ligação ao NGF. Um aptâmero que se liga ao NGF, o qual satisfaz (1) e (2) a seguir: (1) contém a sequência representada por UGAAARAAACC (SEQ ID NO:64) ou CGAAMRAAACU (SEG ID NO:65) e (2) tem um comprimento de base de não mais do que 73.
BR112012024232A 2010-03-24 2011-03-24 "aptâmero de 73 nucleotídeos ou menos, complexo, composição farmacêutica e medicamento anti-dor" BR112012024232A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010068546 2010-03-24
PCT/JP2011/057105 WO2011118682A1 (ja) 2010-03-24 2011-03-24 Ｎｇｆに対するアプタマー及びその使用

Publications (2)

Publication Number Publication Date
BR112012024232A2 BR112012024232A2 (pt) 2016-11-29
BR112012024232A8 true BR112012024232A8 (pt) 2018-02-06

Family

ID=44673231

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024232A BR112012024232A8 (pt) 2010-03-24 2011-03-24 "aptâmero de 73 nucleotídeos ou menos, complexo, composição farmacêutica e medicamento anti-dor"

Country Status (17)

Country Link
US (1) US9175292B2 (pt)
EP (1) EP2551346B1 (pt)
JP (1) JP5027956B2 (pt)
KR (1) KR101806429B1 (pt)
CN (1) CN102844436B (pt)
AU (1) AU2011230388B2 (pt)
BR (1) BR112012024232A8 (pt)
CA (1) CA2794199C (pt)
DK (1) DK2551346T3 (pt)
ES (1) ES2567270T3 (pt)
HR (1) HRP20160378T1 (pt)
HU (1) HUE028939T2 (pt)
IN (1) IN2012KN03036A (pt)
PL (1) PL2551346T3 (pt)
SI (1) SI2551346T1 (pt)
TW (1) TWI500425B (pt)
WO (1) WO2011118682A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598140B2 (en) 2010-04-12 2013-12-03 Somalogic, Inc. Aptamers to β-NGF and their use in treating β-NGF mediated diseases and disorders
AU2012317323B2 (en) * 2011-09-28 2017-10-05 Fujimoto Pharmaceutical Corporation NGF aptamer and application thereof
US20170137818A1 (en) * 2014-03-27 2017-05-18 Ribomic Inc. Aptamer inhibiting biological activity of autotaxin by binding with autotaxin, and use thereof
CN106290914A (zh) * 2015-11-29 2017-01-04 卢美珍 一种用于人脑疾病检测的试剂盒
CN108368509B (zh) * 2015-12-04 2022-03-22 全药工业株式会社 改善了血中滞留性的抗il－17适体
WO2019210194A1 (en) * 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
CN114540349A (zh) * 2020-11-27 2022-05-27 中国科学院分子细胞科学卓越创新中心 结合yb-1蛋白的核酸分子

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
EP0668931B1 (en) 1992-09-29 2006-01-04 Gilead Sciences, Inc. Nucleic acid ligands and methods for producing the same
WO1995007364A1 (en) 1993-09-08 1995-03-16 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands and improved methods for producing the same
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
EP1481090A4 (en) 2002-02-15 2006-08-09 Somalogic Inc METHOD AND REAGENTS FOR DETECTING BINDING OF TARGET MOLECULES BY NUCLEIC ACID ELECTRODES
MXPA05003502A (es) 2002-10-08 2005-09-30 Rinat Neuroscience Corp Metodo para tratar dolor post-quirurgico al administrar un antagonista del factor de crecimiento de nervios y composiciones que contienen el mismo.
AU2003304238A1 (en) 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ATE491444T1 (de) 2003-02-19 2011-01-15 Rinat Neuroscience Corp Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung
KR101504729B1 (ko) 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
AU2007320401B2 (en) 2006-11-14 2012-12-06 Ribomic Inc. Aptamer against midkine and use thereof
AU2009273052B2 (en) * 2008-07-14 2015-09-17 The University Of Tokyo Aptamer against IL-17 and use thereof
EP2354225B1 (en) * 2008-09-24 2015-04-22 Ribomic Inc. Aptamer for ngf and use thereof

Also Published As

Publication number Publication date
AU2011230388A2 (en) 2012-11-15
HUE028939T2 (en) 2017-01-30
AU2011230388A1 (en) 2012-11-01
HRP20160378T1 (hr) 2016-05-20
CN102844436B (zh) 2015-11-25
CA2794199A1 (en) 2011-09-29
US20130052176A1 (en) 2013-02-28
EP2551346A4 (en) 2014-04-30
ES2567270T3 (es) 2016-04-21
US9175292B2 (en) 2015-11-03
IN2012KN03036A (pt) 2015-04-10
JPWO2011118682A1 (ja) 2013-07-04
EP2551346A1 (en) 2013-01-30
EP2551346B1 (en) 2016-01-27
JP5027956B2 (ja) 2012-09-19
TW201201817A (en) 2012-01-16
WO2011118682A1 (ja) 2011-09-29
KR20130028917A (ko) 2013-03-20
TWI500425B (zh) 2015-09-21
DK2551346T3 (en) 2016-04-11
CN102844436A (zh) 2012-12-26
AU2011230388B2 (en) 2016-09-08
SI2551346T1 (sl) 2016-05-31
KR101806429B1 (ko) 2017-12-07
CA2794199C (en) 2017-11-14
PL2551346T3 (pl) 2016-07-29
BR112012024232A2 (pt) 2016-11-29

Similar Documents

Publication Publication Date Title
BR112012024232A8 (pt) "aptâmero de 73 nucleotídeos ou menos, complexo, composição farmacêutica e medicamento anti-dor"
AU2016204248A1 (en) Boron-Containing Molecules
CY1123690T1 (el) Ειδικα για cd40l ικριωματα που προερχονται απο τν3 και μεθοδοι χρησεως αυτων
PH12014502141A1 (en) New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists
MY161088A (en) Agonists of gpr40
BR112015013105A2 (pt) composições de irna de pcsk9 e métodos de uso das mesmas
BR112015018508A2 (pt) moduladores de enzimas modificadoras de metila, suas composições e uso
BR112012029904A2 (pt) métodos de purificação de polipeptídeos
BR112018010381A2 (pt) composições para tratamento de cabelo, condicionadora de cabelo e para alteração da cor do cabelo, sistema para tratamento de cabelo, métodos para tratamento de cabelo e para alteração da cor do cabelo, e, kit de multicompartimentos.
BR112015011244A8 (pt) análogos de compstatina de reação celular, ação longa ou direcionados e composições e métodos relacionados
BR112015023520A2 (pt) purificação do conjugado de anticorpo-fármaco (adc)
BR112015005048A2 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
CR20140197A (es) Compuestos con actividad nematicida
BR112012006035A2 (pt) epratuzumab para uso no tratamento de uma doença autoimune ou inflamatória, e, kit
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
NZ629204A (en) Anti-vla1 (cd49a) antibody pharmaceutical compositions
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
BR122020024446B8 (pt) Compostos para modulação da expressão do receptor do hormônio de crescimento
BR102012012673A8 (pt) célula ns0 modificada, métodos de produzir uma proteína recombinante, de obter uma célula hospedeira de mamífero, de sanitizar uma coluna de cromatografia com afinidade para proteína a e de tratar um paciente sofrendo de esclerose múltipla, vetor, composição, processos para colher uma proteína recombinante de uma cultura de célula e para produzir uma composição purificada de daclizumab, meios, e, tampão
BR112013028449A2 (pt) composições compreendendo partículas de hidrogel
BR112014006587A2 (pt) modulação antisense da expressão de gcgr
MX352245B (es) Formulacion farmaceutica que comprende una droga biofarmaceutica.
BR112015004515A2 (pt) composição imunogênica
BR112014017851A8 (pt) Composição de polímero que compreende nanotubos de carbono
BR112014011254A2 (pt) 2-tiopirimidinonas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: RIBOMIC INC. (JP)

B25A Requested transfer of rights approved

Owner name: RIBOMIC INC. (JP) , FUJIMOTO PHARMACEUTICAL CORPOR

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time